Back
Mesa Laboratories 10K Form
Sell
43
MLAB
Mesa Laboratories
Last Price:
109.09
Seasonality Move:
5.15%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-02-05 | 10Q | MLAB/Mesa Laboratories Quarterly |
2023-11-06 | 10Q | MLAB/Mesa Laboratories Quarterly |
2023-08-03 | 10Q | MLAB/Mesa Laboratories Quarterly |
2023-02-06 | 10Q | MLAB/Mesa Laboratories Quarterly |
2022-11-03 | 10Q | MLAB/Mesa Laboratories Quarterly |
2022-08-04 | 10Q | MLAB/Mesa Laboratories Quarterly |
Receive MLAB News And Ratings
See the #1 stock for the next 7 days that we like better than MLAB
MLAB Financial Statistics
Sales & Book Value
Annual Sales: | $216.19M |
---|---|
Cash Flow: | $3.48M |
Price / Cash Flow: | 15.28 |
Annual Sales: | $29.79 |
Price / Book: | 3.39 |
Profitability
EPS (TTM): | -45.56000 |
---|---|
Net Income (TTM): | $-245.65M |
Gross Margin: | $133.25M |
Return on Equity: | -98.4% |
Return on Assets: | -45.15% |
Mesa Laboratories Earnings Forecast
Key Mesa Laboratories Financial Ratios
- The Gross Profit Margin over the past 37 years for MLAB is 61.64%.
- The Selling, General & Administrative Expenses for MLAB have been equal to 51.57% of Gross Profit Margin.
- The Research & Development expenses have been 8.93% of Revenue.
- The Interest Expense is -2.24% of Operating Income.
- The Net Earning history of MLAB is -117.60% of Total Revenues.
- Per Share Earnings over the last 37 years have been positive in 26 years.
Mesa Laboratories Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Life Sciences Tools & Services |
Sector: | Health Care |
Current Symbol: | MLAB |
CUSIP: | 59064R |
Website: | mesalabs.com |
Debt
Debt-to-Equity Ratio: | 1.27 |
---|---|
Current Ratio: | 0.7 |
Quick Ratio: | 0.42 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 13.81 |
MLAB Technical Analysis vs Fundamental Analysis
Sell
43
Mesa Laboratories (MLAB)
is a Sell
Is Mesa Laboratories a Buy or a Sell?
-
Mesa Laboratories stock is rated a Sell
The current Mesa Laboratories [MLAB] share price is $100.86. The Score for MLAB is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.